Novo Holdings A/S’s CRISPR Therapeutics CRSP Stock Holding History

Novo Holdings A/S’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-223,317	Closed	-$10.2M	–	20
2018 Q1	$10.2M	Hold	223,317	–	–	1.28%	12
2017 Q4	$5.24M	Hold	223,317	–	–	0.74%	13
2017 Q3	$3.99M	Hold	223,317	–	–	0.52%	16
2017 Q2	$3.58M	Hold	223,317	–	–	0.43%	19
2017 Q1	$4.86M	Hold	223,317	–	–	0.52%	20
2016 Q4	$4.52M	Buy	+223,317	New	+$4.17M	0.43%	19

Other funds holding CRSP

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Novo Holdings A/S's CRSP Position: Q2 2018 in Review

Novo Holdings A/S sold out of CRISPR Therapeutics (CRSP) in Q2 2018, closing a stake of 223,317 shares — an estimated $10.2M sold.

Novo Holdings A/S first reported a position in CRSP in Q4 2016 and held it in 6 quarters. The position peaked at $10.2M in Q1 2018. 174 funds tracked by Wall St. Rank hold CRSP as of Q2 2018.

Novo Holdings A/S reported no remaining CRISPR Therapeutics position as of Q2 2018 after selling out during the quarter.
Novo Holdings A/S sold 223,317 CRISPR Therapeutics shares in Q2 2018, an estimated $10.2M.
Novo Holdings A/S first reported a position in CRISPR Therapeutics in Q4 2016 and held it in 6 quarters.
Novo Holdings A/S's CRISPR Therapeutics position peaked at $10.2M in Q1 2018.
174 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2018.

Based on Novo Holdings A/S's 13F filing for Q2 2018, filed 14 Aug 2018.